Tags

Type your tag names separated by a space and hit enter

Breast cancer risk in relation to type of estrogen contained in oral contraceptives.
Contraception 1987; 36(6):595-613C

Abstract

We report analyses designed to address the recent hypothesis that women who use combination-type OCs containing ethinylestradiol (EE) are at increased risk of breast cancer before age 45, if use of such OCs occurs prior to first term pregnancy (FTP). Our findings, based on data from 1679 cases and 1689 controls, 20-44 years of age, from the population-based Cancer and Steroid Hormone Study, are against the hypothesis. The relative risk of breast cancer by duration of exclusive use prior to FTP of OCs containing EE is estimated to be 1.0 (1-12 months EE use), 1.2 (13-48 months EE use), and 0.9 (49+ months EE use). There was no evidence of a latent effect. Among parous women with 49+ months exclusive use prior to FTP of EE-containing OCs, the relative risk of breast cancer was estimated as 0.9 (0-4 years after FTP) and 0.6 (5-9 years after FTP). Among nulliparous women with 49+ months exclusive use of EE-containing OCs, the relative risk of breast cancer was estimated as 1.0 (0-4 years since first use), 0.7 (5-9 years since first use), and 1.1 (10-14 years since first use). With regard to exclusive use of OCs containing mestranol, parous women who used such preparations long-term before their FTP showed no alteration of breast cancer risk, even 15 years or more after pregnancy. Nulliparous women with exclusive use of ME-containing OCs did show elevations in breast cancer risk, but the magnitude of risk in relation to duration of use and latent interval shows no pattern that suggests a cause-effect relationship.

Authors+Show Affiliations

Department of Preventive Medicine and Biometrics, Uniformed Services, University of the Health Sciences, Bethesda, Maryland 20814.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

3446437

Citation

Schlesselman, J J., et al. "Breast Cancer Risk in Relation to Type of Estrogen Contained in Oral Contraceptives." Contraception, vol. 36, no. 6, 1987, pp. 595-613.
Schlesselman JJ, Stadel BV, Murray P, et al. Breast cancer risk in relation to type of estrogen contained in oral contraceptives. Contraception. 1987;36(6):595-613.
Schlesselman, J. J., Stadel, B. V., Murray, P., & Lai, S. H. (1987). Breast cancer risk in relation to type of estrogen contained in oral contraceptives. Contraception, 36(6), pp. 595-613.
Schlesselman JJ, et al. Breast Cancer Risk in Relation to Type of Estrogen Contained in Oral Contraceptives. Contraception. 1987;36(6):595-613. PubMed PMID: 3446437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast cancer risk in relation to type of estrogen contained in oral contraceptives. AU - Schlesselman,J J, AU - Stadel,B V, AU - Murray,P, AU - Lai,S H, PY - 1987/12/1/pubmed PY - 1987/12/1/medline PY - 1987/12/1/entrez KW - Americas KW - Biology KW - Birth Intervals KW - Breast Cancer KW - Cancer KW - Contraception--side effects KW - Contraceptive Agents, Estrogen--side effects KW - Contraceptive Agents, Female--side effects KW - Contraceptive Agents--side effects KW - Contraceptive Methods--side effects KW - Correlation Studies KW - Demographic Factors KW - Developed Countries KW - Developing Countries KW - Diseases KW - Endocrine System KW - Epidemiologic Methods KW - Ethinyl Estradiol--side effects KW - Family Planning KW - Fertility KW - Fertility Measurements KW - First Birth Intervals KW - Hormones KW - Longterm Effects KW - Mestranol--side effects KW - Neoplasms KW - North America KW - Northern America KW - Oral Contraceptives--side effects KW - Parity KW - Physiology KW - Population KW - Population Dynamics KW - Research Methodology KW - Research Report KW - Statistical Studies KW - Studies KW - Time Factors KW - United States SP - 595 EP - 613 JF - Contraception JO - Contraception VL - 36 IS - 6 N2 - We report analyses designed to address the recent hypothesis that women who use combination-type OCs containing ethinylestradiol (EE) are at increased risk of breast cancer before age 45, if use of such OCs occurs prior to first term pregnancy (FTP). Our findings, based on data from 1679 cases and 1689 controls, 20-44 years of age, from the population-based Cancer and Steroid Hormone Study, are against the hypothesis. The relative risk of breast cancer by duration of exclusive use prior to FTP of OCs containing EE is estimated to be 1.0 (1-12 months EE use), 1.2 (13-48 months EE use), and 0.9 (49+ months EE use). There was no evidence of a latent effect. Among parous women with 49+ months exclusive use prior to FTP of EE-containing OCs, the relative risk of breast cancer was estimated as 0.9 (0-4 years after FTP) and 0.6 (5-9 years after FTP). Among nulliparous women with 49+ months exclusive use of EE-containing OCs, the relative risk of breast cancer was estimated as 1.0 (0-4 years since first use), 0.7 (5-9 years since first use), and 1.1 (10-14 years since first use). With regard to exclusive use of OCs containing mestranol, parous women who used such preparations long-term before their FTP showed no alteration of breast cancer risk, even 15 years or more after pregnancy. Nulliparous women with exclusive use of ME-containing OCs did show elevations in breast cancer risk, but the magnitude of risk in relation to duration of use and latent interval shows no pattern that suggests a cause-effect relationship. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/3446437/Breast_cancer_risk_in_relation_to_type_of_estrogen_contained_in_oral_contraceptives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(87)90033-3 DB - PRIME DP - Unbound Medicine ER -